📗 Cite This Artifact
Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP
Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Gasotransmitter</td>
<td>Finding in Tauopathy</td>
</tr>
<tr>
<td class="label">NO</td>
<td>nNOS uncoupling → peroxynitrite formation</td>
</tr>
<tr>
<td class="label">CO</td>
<td>Reduced HO-1 activity</td>
</tr>
<tr>
<td class="label">H2S</td>
<td>CBS/CSE downregulation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">NANT-3</td>
<td>nNOS selective</td>
</tr>
<tr>
<td class="label">7-NI</td>
<td>nNOS inhibitor</td>
</tr>
<tr>
<td class="label">TRIM</td>
<td>nNOS-PDI inhibitor</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">L-arginine</td>
<td>NO precursor</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>eNOS upregulation</td>
</tr>
<tr>
<td class="label">ACE inhibitors</td>
<td>eNOS activation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">L-NIL</td>
<td>iNOS selective</td>
</tr>
<tr>
<td class="label">S-methylisothiourea</td>
<td>iNOS inhibitor</td>
</tr>
<tr>
<td class="label">ONO-1714</td>
<td>iNOS inhibitor</td>
</tr>
<tr>
<td class="label">Compound</td>
Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Gasotransmitter</td>
<td>Finding in Tauopathy</td>
</tr>
<tr>
<td class="label">NO</td>
<td>nNOS uncoupling → peroxynitrite formation</td>
</tr>
<tr>
<td class="label">CO</td>
<td>Reduced HO-1 activity</td>
</tr>
<tr>
<td class="label">H2S</td>
<td>CBS/CSE downregulation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">NANT-3</td>
<td>nNOS selective</td>
</tr>
<tr>
<td class="label">7-NI</td>
<td>nNOS inhibitor</td>
</tr>
<tr>
<td class="label">TRIM</td>
<td>nNOS-PDI inhibitor</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">L-arginine</td>
<td>NO precursor</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>eNOS upregulation</td>
</tr>
<tr>
<td class="label">ACE inhibitors</td>
<td>eNOS activation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">L-NIL</td>
<td>iNOS selective</td>
</tr>
<tr>
<td class="label">S-methylisothiourea</td>
<td>iNOS inhibitor</td>
</tr>
<tr>
<td class="label">ONO-1714</td>
<td>iNOS inhibitor</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Ebselen</td>
<td>GPx mimetic, ONOO⁻ scavenger</td>
</tr>
<tr>
<td class="label">Tempol</td>
<td>SOD mimetic</td>
</tr>
<tr>
<td class="label">MnTBAP</td>
<td>SOD mimetic, ONOO⁻ decomposer</td>
</tr>
<tr>
<td class="label">FeTPPS</td>
<td>ONOO⁻ decomposer</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>CO Release Profile</td>
</tr>
<tr>
<td class="label">CORM-2</td>
<td>Slow release (Ru carbonyl)</td>
</tr>
<tr>
<td class="label">CORM-3</td>
<td>Fast release (water-soluble)</td>
</tr>
<tr>
<td class="label">CORM-401</td>
<td>Mitochondria-targeted</td>
</tr>
<tr>
<td class="label">DI-1</td>
<td>Light-activated</td>
</tr>
<tr>
<td class="label">ALF-186</td>
<td>Slow CO release</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Hemin</td>
<td>HO-1 transcription</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>Nrf2 → HO-1</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>Nrf2 → HO-1</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>HO-1 upregulation</td>
</tr>
<tr>
<td class="label">Donor</td>
<td>Release Profile</td>
</tr>
<tr>
<td class="label">NaHS</td>
<td>Fast release</td>
</tr>
<tr>
<td class="label">GYY4137</td>
<td>Slow, sustained</td>
</tr>
<tr>
<td class="label">AP39</td>
<td>Mitochondria-targeted</td>
</tr>
<tr>
<td class="label">AP123</td>
<td>mitochondria-targeted</td>
</tr>
<tr>
<td class="label">A-419259</td>
<td>Slow release</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>CBS upregulation</td>
</tr>
<tr>
<td class="label">Alpha-lipoic acid</td>
<td>Sulfur donor</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>Cysteine source</td>
</tr>
<tr>
<td class="label">Vitamin B6</td>
<td>CBS cofactor</td>
</tr>
<tr>
<td class="label">Magnesium</td>
<td>CBS cofactor</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Sodium sulfite</td>
<td>H2S release</td>
</tr>
<tr>
<td class="label">SF100</td>
<td>CBS activator</td>
</tr>
<tr>
<td class="label">SG1002</td>
<td>H2S donor</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Synergy Mechanism</td>
</tr>
<tr>
<td class="label">CO + H2S</td>
<td>Mitochondrial protection</td>
</tr>
<tr>
<td class="label">NO + H2S</td>
<td>Nrf2 activation</td>
</tr>
<tr>
<td class="label">CO + NO</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">H2S + eNOS</td>
<td>Vasoprotection</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Contraindication</td>
</tr>
<tr>
<td class="label">H2S donors</td>
<td>Severe liver disease, sulfide intolerance</td>
</tr>
<tr>
<td class="label">CORMs</td>
<td>Active infection, pregnancy</td>
</tr>
<tr>
<td class="label">NOS inhibitors</td>
<td>Hypotension, liver dysfunction</td>
</tr>
<tr>
<td class="label">L-arginine</td>
<td>Herpes virus (arginine promotes replication)</td>
</tr>
<tr>
<td class="label">Current Medication</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Blood pressure meds</td>
<td>Additive hypotension</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety Profile</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Combination Potential</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>33/60</td>
</tr>
</table>
Gasotransmitters—nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S)—are endogenously produced gaseous signaling molecules that play critical roles in neuronal function, neuroinflammation, and cell survival. Dysregulation of gasotransmitter signaling contributes to tauopathy pathology, making this pathway an emerging therapeutic target for CBS/PSP.
Therapeutic Rationale
Why Gasotransmitters Matter in Tauopathy
Gasotransmitter Deficiency in CBS/PSP
1. Nitric Oxide Signaling Modulation
Overview
Nitric oxide is produced by three nitric oxide synthase (NOS) isoforms:
- nNOS (neuronal): Constitutively expressed, Ca²⁺-dependent
- eNOS (endothelial): Vascular regulation, neuroprotective
- iNOS (inducible): Pro-inflammatory, high-output NO production
Therapeutic Approaches
1.1 nNOS-Selective Inhibitors
Rationale: Excessive nNOS activity produces peroxynitrite (ONOO⁻), which nitrates tau and promotes aggregation.
1.2 eNOS Enhancers
Rationale: eNOS-derived NO is neuroprotective through vasodilation and anti-inflammatory effects.
1.3 iNOS Inhibitors
Rationale: iNOS upregulation in tauopathy drives neuroinflammation.
1.4 Peroxynitrite Scavengers
Rationale: Neutralize peroxynitrite formed from NO + superoxide.
2. Carbon Monoxide-Releasing Molecules (CORMs)
Overview
CO is produced by heme oxygenase (HO) enzymes:
- HO-1 (inducible): Stress-responsive, antioxidant
- HO-2 (constitutive): Physiologic CO production
CORMs release controlled amounts of CO to achieve therapeutic effects without toxicity.
Therapeutic Benefits
Clinical-Stage CORMs
Dosing Considerations
- Low-dose CO: Anti-inflammatory, neuroprotective
- High-dose CO: Cytotoxic, avoid
- Delivery: Inhalation, CORM administration, HO-1 inducers
HO-1 Inducers
3. Hydrogen Sulfide (H2S) Donors
Overview
H2S is produced by:
- CBS (cystathionine β-synthase): Brain predominant
- CSE (cystathionine γ-lyase): Peripheral/cascular
- 3-MST (3-mercaptopyruvate sulfurtransferase): Mitochondrial
Therapeutic Benefits
H2S Donor Classes
3.1 Classic H2S Donors
3.2 Natural H2S Boosters
3.3 Clinical Candidates
4. Gasotransmitter Combination Therapies
Rationale
Combining gasotransmitters can achieve synergistic neuroprotection through complementary mechanisms:
Evidence-Based Combinations
Multi-Target Protocols
Protocol 1: Anti-Inflammatory Stack
- Morning: H2S donor (GYY4137) + Curcumin
- Evening: CO-RM (low-dose) + Sulforaphane
- Rationale: Sequential Nrf2 activation + anti-inflammatory
Protocol 2: Mitochondrial Protection
- AP39 (mitochondria-targeted H2S)
- Low-dose CORM-3
- Alpha-lipoic acid
- CoQ10
- Rationale: Multi-level mitochondrial support
Protocol 3: Neurovascular Unit Support
- L-arginine (NO precursor)
- Hemin (HO-1 inducer)
- Vitamin D
- Rationale: BBB integrity + cerebral perfusion
5. Clinical Implementation Protocol
Patient Assessment
Before initiating gasotransmitter therapy:
- Complete metabolic panel (liver, kidney function)
- Blood count
- Blood pressure monitoring
- Cognitive assessment (MoCA, PSPRS)
- Weekly BP for first month
- Monthly liver function
- Quarterly cognitive assessment
Recommended Approach for CBS/PSP Patient
Phase 1: Foundation (Weeks 1-4)
- Sulforaphane 30mg daily (Nrf2/HO-1 activation)
- Alpha-lipoic acid 600mg daily (mitochondrial support, H2S boost)
- Monitor: Blood pressure, tolerance
Phase 2: Add Targeted Therapy (Weeks 5-12)
- Continue Phase 1 agents
- Add: GYY4137 50mg daily OR natural H2S booster
- Optional: Low-dose curcumin (HO-1 inducer)
Phase 3: Optimization (Week 13+)
- Based on response:
- Add mitochondria-targeted H2S (AP39) if tolerated
- Consider CO-RM if neuroinflammation prominent
- Avoid NOS inhibitors unless peroxynitrite clearly elevated
Contraindications
Drug Interactions
6. NET Assessment
7. Patient-Specific Recommendations
For This Patient (50-year-old male, CBS/PSP)
Priority: Moderate - Consider after higher-priority therapies initiated
Recommended Initial Protocol:
Rationale: This patient has high priority on disease modification. Gasotransmitter therapy provides:
- Anti-inflammatory effects (addressing neuroinflammation)
- Mitochondrial support (addressing bioenergetic dysfunction)
- Nrf2 activation (antioxidant response)
- Protein homeostasis support (via S-persulfidation)
- 2-4 weeks: Initial tolerance assessment
- 8-12 weeks: May observe improved energy, reduced fatigue
- 6+ months: Long-term neuroprotection goals
8. Cross-Links to Related Pages
- [Nitric Oxide Signaling Mechanism](/mechanisms/nitric-oxide-signaling-neurodegeneration)
- [Hydrogen Sulfide Signaling Mechanism](/mechanisms/hydrogen-sulfide-signaling-neurodegeneration)
- [Gasotransmitters in Neuroprotection](/mechanisms/gasotransmitters-neuroprotection)
- [Nitric Oxide Modulation Therapy](/therapeutics/nitric-oxide-modulation-therapy)
- [Antioxidant and Redox Therapy](/therapeutics/personalized-treatment-plan-atypical-parkinsonism#section-162-advanced-antioxidant-and-redox-therapy)
- [Mitochondrial Dynamics](/therapeutics/personalized-treatment-plan-atypical-parkinsonism#mitochondrial-dynamics-biogenesis)
- [Neuroinflammation](/mechanisms/neuroinflammation-psp)
References
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
- [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
- [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-section-250-advanced-gasotransmitter-therapy-cbs-psp |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-2630b84017c5 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-250-advanced-gasotransmitter-therapy-cbs-psp'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-section-250-advanced-gasotransmitter-therapy-cbs-psp?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP](http://scidex.ai/artifact/wiki-therapeutics-section-250-advanced-gasotransmitter-therapy-cbs-psp)
http://scidex.ai/artifact/wiki-therapeutics-section-250-advanced-gasotransmitter-therapy-cbs-psp